Arvinas logo

BRD4 Degradation by PROTACs Represents a More Effective Therapeutic Strategy than BRD4 Inhibitors in DLBCL

Jing Lu Ph.D., et al.

December 1, 2015
American Society of Hematology 57th Annual Meeting and Exposition
Skip to content